Alzheimer’s is a leading cause for disability and dependency in later life. We’re working towards changing this.
Alzheimer’s Affects Everyone
1 out of 9 people over the age of 65 suffer from Alzheimer’s disease. But really, it affects everyone. A progressive disease, initial symptoms of Alzheimer’s include memory loss. During late-stage Alzheimer’s, individuals lose the ability to care for themselves and can no longer respond to their environment. While frustrating for Alzheimer patients, friends and family members are forced to watch as their loved one transforms into a silhouette of their former, healthy selves.
A characteristic of Alzheimer’s disease is the accumulation of beta-amyloid plaques in the brain. Since the retina is an extension of the brain, this provides clinicians and researchers with critical access for identifying beta-amyloid plaques, known as a key biomarker of Alzheimer’s. In turn, leading to the early detection of this horrible disease.
Clinical Trials – Changing the Future of Alzheimer’s
As a first step, patients will undergo a full eye exam by an ophthalmologist. During this visit, patients will be imaged with Optina Diagnostics’ hyperspectral research MHRC camera.
This imaging test takes less than one second, during which patients will see a rainbow of colors. The overall visit should last less than an hour.
During a second visit, patients will undergo a PET scan using a beta-amyloid tracer. PET is an imaging test that enables radiologists to detect diseases within the body. This scan uses a special dye containing radioactive tracers. Injected into a vein in the patient’s arm, these tracers are absorbed by the brain and tissues for diagnostic purposes.